SCHEMBL23769025

SCHEMBL23769025

O=C(Nc1ccc(F)cc1)Nc1ccc2c(c1)SCC(=O)N2Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
MAPT P10636 5/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 4/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
KCNJ6 P48051 1/20 0.46
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
LMNA P02545 1/20 0.45
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23768798 0.92 TSHR (0.60) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23768800 0.85 MAPT (0.58) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23768801 0.83 MAPT (0.45) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23769022 0.82 MAPT (0.56) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL30882832 0.81 STING1 (0.49) MAPTSMN1; SMN2POLBALDH1A1CYP2C9
SCHEMBL25037393 0.81 STING1 (0.49) MAPTSMN1; SMN2POLBALDH1A1CYP2C9
SCHEMBL23769024 0.81 USP2 (0.61) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23769074 0.80 MAPT (0.53) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL29979355 0.80 MAPT (0.53) TSHRMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL23768995 0.80 ALDH1A1 (0.56) MAPTMEN1KMT2ASMN1; SMN2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151304-B Small molecule interferon gene stimulating factor (STING) antagonists 库拉德夫制药私人有限公司 2025-02-11 CN claimed
CN-115151304-A Small molecule interferon gene stimulating factor (STING) antagonists 库拉德夫制药私人有限公司 2022-10-04 CN claimed
US-20230124361-A1 SMALL MOLECULE STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-04-20 US disclosed
US-20230124361-A1 SMALL MOLECULE STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2023-04-20 US disclosed
WO-2021161230-A1 SMALL MOLECULE STING ANTAGONISTS CURADEV PHARMA PVT. LTD. (IN) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124361-A1 SMALL MOLECULE STING ANTAGONISTS STING1, CGAS, MAVS TSHR 1353/4885MAPT 3716/4885MEN1 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.